- Home
- AVPT vs SRPT Comparison
AVPT vs SRPT Comparison
Compare AVPT & SRPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AVPT | SRPT |
|---|---|---|
| Founded | 2001 | 1980 |
| Country | United States | United States |
| Employees | 3443 | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.0B |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | AVPT | SRPT |
|---|---|---|
| Price | $13.43 | $22.50 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 12 | 29 |
| Target Price | $16.64 | ★ $25.85 |
| AVG Volume (30 Days) | 1.6M | ★ 2.8M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.99 |
| Revenue | N/A | ★ $2,198,237,000.00 |
| Revenue This Year | $25.00 | N/A |
| Revenue Next Year | $19.63 | N/A |
| P/E Ratio | $1,348.94 | ★ $7.78 |
| Revenue Growth | N/A | ★ 15.58 |
| 52 Week Low | $8.84 | $14.68 |
| 52 Week High | $16.77 | $25.32 |
Technical Indicators
Market Signals| Indicator | AVPT | SRPT |
|---|---|---|
| Relative Strength Index (RSI) | 54.88 | 73.88 |
| Support Level | $12.92 | $15.40 |
| Resistance Level | $13.71 | $23.71 |
| Average True Range (ATR) | 0.41 | 1.34 |
| MACD | -0.03 | 0.44 |
| Stochastic Oscillator | 49.84 | 93.98 |
Price Performance
Historical ComparisonAbout AVPT AvePoint Inc.
AvePoint Inc is a provider of modern data protection, enabling organizations to secure, govern, and operationalize data at scale across cloud ecosystems. Customers rely on the AvePoint Confidence Platform to reduce risk, improve operational efficiency, and accelerate digital transformation as it adopt cloud collaboration and artificial intelligence (AI)-driven developed tools and workflows. Its products and services are sold throughout the world, through direct and indirect sales channels.
About SRPT Sarepta Therapeutics Inc. (DE)
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.